These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 9436257)

  • 1. Effects of arginine, growth hormone-releasing hormone (GHRH) and neostigmine administered singly or in paired combinations on growth hormone (GH) release in pigs.
    Cochard A; Guilhermet R; Bonneau M
    Reprod Nutr Dev; 1997; 37(5):589-98. PubMed ID: 9436257
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Growth hormone (GH) responsiveness to combined administration of arginine and GH-releasing hormone does not vary with age in man.
    Ghigo E; Goffi S; Nicolosi M; Arvat E; Valente F; Mazza E; Ghigo MC; Camanni F
    J Clin Endocrinol Metab; 1990 Dec; 71(6):1481-5. PubMed ID: 2229304
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Arginine and growth hormone-releasing hormone restore the blunted growth hormone-releasing activity of hexarelin in elderly subjects.
    Arvat E; Gianotti L; Grottoli S; Imbimbo BP; Lenaerts V; Deghenghi R; Camanni F; Ghigo E
    J Clin Endocrinol Metab; 1994 Nov; 79(5):1440-3. PubMed ID: 7962341
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low doses of either intravenously or orally administered arginine are able to enhance growth hormone response to growth hormone releasing hormone in elderly subjects.
    Ghigo E; Ceda GP; Valcavi R; Goffi S; Zini M; Mucci M; Valenti G; Cocchi D; Müller EE; Camanni F
    J Endocrinol Invest; 1994 Feb; 17(2):113-7. PubMed ID: 8006330
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Further evidence of cholinergic impairment of the neuroendocrine control of the GH secretion in Down's syndrome.
    Beccaria L; Marziani E; Manzoni P; Arvat E; Valetto MR; Gianotti L; Ghigo E; Chiumello G
    Dement Geriatr Cogn Disord; 1998; 9(2):78-81. PubMed ID: 9524798
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of acipimox, an antilipolytic drug, on the growth hormone (GH) response to GH-releasing hormone alone or combined with arginine in obesity.
    Maccario M; Procopio M; Grottoli S; Oleandri SE; Boffano GM; Taliano M; Camanni F; Ghigo E
    Metabolism; 1996 Mar; 45(3):342-6. PubMed ID: 8606641
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low dose orally administered arginine is able to enhance both basal and growth hormone-releasing hormone-induced growth hormone secretion in normal short children.
    Bellone J; Bartolotta E; Cardinale G; Arvat E; Cherubini V; Aimaretti G; Maccario M; Mucci M; Camanni F; Ghigo E
    J Endocrinol Invest; 1993; 16(7):521-5. PubMed ID: 8227981
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Arginine potentiates but does not restore the blunted growth hormone response to growth hormone-releasing hormone in obesity.
    Ghigo E; Procopio M; Boffano GM; Arvat E; Valente F; Maccario M; Mazza E; Camanni F
    Metabolism; 1992 May; 41(5):560-3. PubMed ID: 1588839
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Arginine stimulates growth hormone secretion by suppressing endogenous somatostatin secretion.
    Alba-Roth J; Müller OA; Schopohl J; von Werder K
    J Clin Endocrinol Metab; 1988 Dec; 67(6):1186-9. PubMed ID: 2903866
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intranasal administration of neostigmine potentiates both intravenous and intranasal growth hormone (GH)-releasing hormone-induced GH release in short children.
    Ghigo E; Procopio M; Bellone J; Mazza E; Mucci M; Boghen MF; Müller EE; Camanni F
    J Clin Endocrinol Metab; 1991 Feb; 72(2):467-70. PubMed ID: 1991816
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Short-term fasting in obesity fails to restore the blunted GH responsiveness to GH-releasing hormone alone or combined with arginine.
    Procopio M; Maccario M; Grottoli S; Oleandri SE; Boffano GM; Camanni F; Ghigo E
    Clin Endocrinol (Oxf); 1995 Dec; 43(6):665-9. PubMed ID: 8736266
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The decrease in growth hormone (GH) response after repeated stimulation with GH-releasing hormone is partly caused by an elevation of somatostatin tonus.
    Reichardt B; Schrader M; Mojto J; Mehltretter G; Müller OA; Schopohl J
    J Clin Endocrinol Metab; 1996 May; 81(5):1994-8. PubMed ID: 8626871
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Arginine potentiates the GHRH- but not the pyridostigmine-induced GH secretion in normal short children. Further evidence for a somatostatin suppressing effect of arginine.
    Ghigo E; Bellone J; Mazza E; Imperiale E; Procopio M; Valente F; Lala R; De Sanctis C; Camanni F
    Clin Endocrinol (Oxf); 1990 Jun; 32(6):763-7. PubMed ID: 1974484
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of 15-day treatment with growth-hormone-releasing hormone alone or combined with different doses of arginine on the reduced somatotrope responsiveness to the neurohormone in normal aging.
    Ghigo E; Ceda GP; Valcavi R; Goffi S; Zini M; Mucci M; Valenti G; Muller EE; Camanni F
    Eur J Endocrinol; 1995 Jan; 132(1):32-6. PubMed ID: 7850007
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutual priming effects of GHRH and arginine on GH secretion: informative procedure for evaluating GH secretory dynamics.
    Sato T; Igarashi N; Miyagawa K; Shimizu M; Nishikawa T; Hashimoto T
    Endocrinol Jpn; 1990 Aug; 37(4):501-9. PubMed ID: 1982090
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential effects of arginine on growth hormone releasing hormone and insulin induced growth hormone secretion.
    Koppeschaar HP; ten Horn CD; Thijssen JH; Page MD; Dieguez C; Scanlon MF
    Clin Endocrinol (Oxf); 1992 May; 36(5):487-90. PubMed ID: 1617799
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Arginine counteracts the inhibitory effect of recombinant human insulin-like growth factor I on the somatotroph responsiveness to growth hormone-releasing hormone in humans.
    Gianotti L; Maccario M; Lanfranco F; Ramunni J; Di Vito L; Grottoli S; Muller EE; Ghigo E; Arvat E
    J Clin Endocrinol Metab; 2000 Oct; 85(10):3604-8. PubMed ID: 11061509
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduction of the somatotrope responsiveness to GHRH and Hexarelin but not to arginine plus GHRH in hyperprolactinemic patients.
    Grottoli S; Razzore P; Arvat E; Oleandri SE; Rossetto R; Ciccarelli E; Camanni F; Ghigo E
    J Endocrinol Invest; 1997 Nov; 20(10):597-602. PubMed ID: 9438917
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evidence against depletion of the growth hormone (GH)-releasable pool in human primary hypothyroidism: studies with GH-releasing hormone, pyridostigmine, and arginine.
    Valcavi R; Valente F; Dieguez C; Zini M; Procopio M; Portioli I; Ghigo E
    J Clin Endocrinol Metab; 1993 Sep; 77(3):616-20. PubMed ID: 8103770
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Growth hormone (GH) responses to GH-releasing hormone alone or combined with arginine in patients with adrenal incidentaloma: evidence for enhanced somatostatinergic tone.
    Terzolo M; Bossoni S; Alí A; Doga M; Reimondo G; Milani G; Peretti P; Manelli F; Angeli A; Giustina A
    J Clin Endocrinol Metab; 2000 Mar; 85(3):1310-5. PubMed ID: 10720081
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.